Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.
Mascilini F, Amadio G, Di Stefano MG, Ludovisi M, Di Legge A, Conte C, De Vincenzo R, Ricci C, Masciullo V, Salutari V, Scambia G, Ferrandina G. Mascilini F, et al. Among authors: amadio g. Onco Targets Ther. 2014 Jul 12;7:1273-84. doi: 10.2147/OTT.S51550. eCollection 2014. Onco Targets Ther. 2014. PMID: 25050069 Free PMC article. Review.
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients.
Lorusso D, Scambia G, Amadio G, di Legge A, Pietragalla A, De Vincenzo R, Masciullo V, Di Stefano M, Mangili G, Citterio G, Mantori M, Lambiase A, Bordignon C. Lorusso D, et al. Among authors: amadio g. Br J Cancer. 2012 Jun 26;107(1):37-42. doi: 10.1038/bjc.2012.233. Epub 2012 May 29. Br J Cancer. 2012. PMID: 22644293 Free PMC article. Clinical Trial.
Emerging drugs for ovarian cancer.
Lorusso D, Pietragalla A, Mainenti S, Di Legge A, Amadio G, Scambia G. Lorusso D, et al. Among authors: amadio g. Expert Opin Emerg Drugs. 2010 Dec;15(4):635-52. doi: 10.1517/14728214.2010.502888. Epub 2010 Jul 7. Expert Opin Emerg Drugs. 2010. PMID: 20604741 Review.
Controversy in treatment of advanced ovarian cancer.
Scambia G, Salutari V, Amadio G. Scambia G, et al. Among authors: amadio g. Lancet Oncol. 2013 Sep;14(10):920-1. doi: 10.1016/S1470-2045(13)70391-7. Lancet Oncol. 2013. PMID: 23993374 No abstract available.
Emerging drugs for endometrial cancer.
Amadio G, Masciullo V, Ferrandina MG, Scambia G. Amadio G, et al. Expert Opin Emerg Drugs. 2014 Dec;19(4):497-509. doi: 10.1517/14728214.2014.971752. Epub 2014 Oct 21. Expert Opin Emerg Drugs. 2014. PMID: 25330855 Review.
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.
Lorusso D, Scambia G, Pignata S, Sorio R, Amadio G, Lepori S, Mosconi A, Pisano C, Mangili G, Maltese G, Sabbatini R, Artioli G, Gamucci T, Di Napoli M, Capoluongo E, Ludovini V, Raspagliesi F, Ferrandina G. Lorusso D, et al. Among authors: amadio g. Ann Oncol. 2016 Mar;27(3):487-93. doi: 10.1093/annonc/mdv608. Epub 2015 Dec 17. Ann Oncol. 2016. PMID: 26681678 Free article. Clinical Trial.
61 results